Previous studies have shown that the NF‐κB pathway can be used as a promoter or tumor suppressor to promote cancer progression by regulating inflammation and immune responses.[9] NF‐κB can induce hypoxia inducible factor‐1α (HIF‐1α) expression and increase glucose transporter‐1 expression and glycolytic enzyme activity.[10] Inspired by the literature above, we hypothesize that GJB2 activates the NF‐κB pathway, which uses HIF‐1α/GLUT‐1 to bring more glucose into HCC cells. Here, SLC2A1 is linked to hepatocellular carcinoma.